Amgen Discontinuing Future Development Of AMG 513; To Continue Phase 1 Trial Of AMG 513 In Adults With Obesity
Amgen Discontinuing Future Development Of AMG 513; To Continue Phase 1 Trial Of AMG 513 In Adults With Obesity
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day